Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oei Ju Lee, Kirby Adrienne, Travadi Javeed, Davis Peter, Wright Ian, Ghadge Alpana, Yeung Carbo, Cruz Melinda, Keech Anthony, Hague Wendy, Lui Kei, Vento Maximo, Gordon Adrienne, De Waal Koert, Chaudhari Tejasvi, Hong Timothy Sui Loong, Morris Scott, Kushnir Alla, Bonney Dennis, Tracy Mark, Kumar Kishore, Chhnia Amitoj Singh, Baral Vijay R, Muniyappa Prasana, Cheah Fook Choe, Sarnadgouda Prashant, Rajadurai Victor Samuel, Balakrishnan Umamaheshwari, Oleti Tejo Pratap, Aldecoa-Bilbao Victoria, Couce Maria-Luz, Collados Caridad Tapia, Fernández Raquel Escrig, Moliner Elisender, Ruiz Gonzalez Maria Dolores, Singhal Mohit, Agrawal Gopal, Singh Jaykishore, Pal Somalika, Nayya Siddarth, Arora Rohit, Amboiram Prakash, Simes John, Tarnow-Mordi William, TORPIDO30/60 Collaborative Group
Аннотация
OBJECTIVE: To compare outcomes of newborns born at 23 to 28 weeks' gestation resuscitated with initial Fio2 of 0.6 vs 0.3.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted in 31 maternity hospitals in 6 countries. Consent by waiver was obtained in Australia, certain institutions in India, and Malaysia; prospective informed consent was obtained in certain institutions in India and all institutions in Singapore, Spain, and the US. Infants due at 23 to 28 weeks' gestation were randomized shortly before birth. Those with congenital abnormalities affecting oxygenation, neurodevelopment, or survival were excluded. Randomization was conducted from September 2018 to September 2024, with follow-up expected to close in September 2026.
INTERVENTION: Infants were randomized (1:1) to receive an initial Fio2 of 0.6 or 0.3; Fio2 was titrated to meet standard targets for oxygen saturation by pulse oximetry in the first 10 minutes or for clinical needs. Clinicians and those assessing outcomes were not blinded to group assignment.
MAIN OUTCOMES AND MEASURES: The primary outcome was death and brain injury at 36 weeks' corrected gestational age; secondary outcomes were the individual components of the primary outcome.
RESULTS: A total of 1641 newborns were randomized. The primary analysis included 728 newborns randomized to receive an Fio2 of 0.6 and 741 to an Fio2 of 0.3 after excluding 172 newborns, mostly for birth after 28 weeks' gestation and transfer to another hospital before birth (54% female). Rates of escalation to Fio2 of 1.0 were similar between the groups (Fio2 of 0.6: 41%; Fio2 of 0.3: 38%). Primary outcome information was ascertained in 1423 newborns (96.9%). Death or brain injury at 36 weeks' corrected gestational age occurred in 330 of 703 newborns (46.9%) assigned to the Fio2 of 0.6 group vs 344 of 720 (47.8%) assigned to the Fio2 of 0.3 group (relative risk, 0.98 [95% CI, 0.89-1.09]).
CONCLUSIONS AND RELEVANCE: Initiating resuscitation of preterm infants with Fio2 of 0.6 vs 0.3 did not affect the risk of death or brain injury by 36 weeks' corrected gestational age. These results lay a foundation for future trials evaluating the effectiveness and safety of using higher initial Fio2 levels for preterm infant resuscitation.
TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000879268.